Date:3/1/2010

the NDA for ANX-530 on December 30, 2009.  Based on current regulations, once an NDA is submitted to the FDA, FDA has 60 days to preliminarily review the NDA submission and assess whether the NDA is sufficiently complete to permit a substantive review. If it determines that the NDA is not sufficiently complete, the FDA issues a refuse to file letter to the applicant. ADVENTRX plans to request a meeting with the FDA as soon as possible to discuss its comments on the NDA submission and to reach an understanding on what would be required for the ANX-530 NDA to be accepted for review.  

Conference Call and Webcast

ADVENTRX will hold a conference call on Monday, March 1, 2010 beginning at 9:00 a.m. Eastern time to review the developments discussed in this news release.  Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com.  A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and enterin
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. ADVENTRX Announces Management Promotions
2. ADVENTRX Appoints Icahn Representative to Board of Directors
3. ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
4. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
5. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
6. ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
7. ADVENTRX Pharmaceuticals Announces Closing of Financing
8. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
9. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results